Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab Plus Gemcitabine in SWI/SNF Altered Metastatic Pancreatic Adenocarcinoma
NCT06790602Phase 2
Key facts
- Status
- Recruiting
- Start
- May 2026
- Primary completion
- Jul 2028
- Countries
- 1
- Sponsor
- University of California, San Diego
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Drugs
- cemiplimab
- Conditions
- pancreatic ductal adenocarcinoma (PDAC)
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of California, San Diego. Primary endpoint: Overall survival at 7 months. Started May 2026; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Cemiplimab Plus Gemcitabine
Combination therapy of cemiplimab plus gemcitabine
03
Who it enrols
Adults with metastatic pancreatic ductal adenocarcinoma harboring SWI/SNF alterations, who have received one prior line of chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) and no prior immunotherapy.
04
Endpoints
Primary
Overall survival
Beyond the preview
Go deeper on NCT06790602.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790602.